Multiple studies have shown that the anti-B-Cell maturation antigen (BCMA) or combination of anti-CD19 and anti-BCMA CAR-T cells has an encouraging activity in the treatment of R/R MM, with an overall response rate of 70-100% (1–4). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.